Results 41 to 50 of about 127,568 (322)

Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Cardiogenic shock from most causes has unfavorable prognosis. Hypertrophic cardiomyopathy (HCM) can uncommonly present with apical ballooning and shock in association with sudden development of severe and unrelenting left ventricular (LV ...
Mark V. Sherrid, Daniel G. Swistel, Iacopo Olivotto, Maurizio Pieroni, Omar Wever‐Pinzon, Katherine Riedy, Richard G. Bach, Mustafa Husaini, Sharon Cresci, Alex Reyentovich, Daniele Massera, Martin S. Maron, Barry J. Maron, Bette Kim   +13 more
doaj   +1 more source

Extreme hypertrophic cardiomyopathy [PDF]

Heart, 2003
A 21 year old Jamaican woman with hypertrophic cardiomyopathy (HCM) was referred for sudden death risk assessment. The initial diagnosis of HCM was made at the age of 13 years and mild exertional dyspnoea has occurred since age 15 (New York Heart Association functional class II), but without syncope or chest pain. There is no …
B J, Maron, S A, Casey, A K, Almquist
openaire   +2 more sources

Cardiac hypertrophy and heart failure: from the case to review of literature [PDF]

, 2016
In response to an increased workload due to physiological or pathological stimuli, the heart may undergo a process of growth with increased muscle mass called cardiac hypertrophy. It is a particular mechanism of long term compensation used by the heart
Massoni, Francesco, Onofri, Emanuela, Ricci, Lidia, Ricci, Serafino, Simeone, Claudio   +4 more
core   +1 more source

Hypertrophic Obstructive Cardiomyopathy [PDF]

Deutsches Ärzteblatt international, 2019
Hypertrophic cardiomyopathy (HCM) is caused by mutations in a number of genes. Its prevalence is 0.2% to 0.6%.This review is based on publications retrieved by a selective literature search and on the authors' clinical experi- ence.70% of patients with HCM suffer from the obstructive type of the condition, clinically characterized by highly dynamic and
Angelika, Batzner, Hans-Joachim, Schäfers, Konstantin V, Borisov, Hubert, Seggewiß   +3 more
openaire   +2 more sources

Seipin‐Mediated Lipid Droplet Formation in Cardiomyocytes Ameliorates Cardiac Ischemia/Reperfusion Injury

Advanced Science, EarlyView.
Lipid droplets (LDs) protect the heart against lipotoxicity in cardiac ischemia/reperfusion (I/R) injury; however, they are insufficient to prevent cardiomyocyte death. Seipin plays a central role in the insufficient formation of LDs, subsequent lipotoxicity, and myocardial injury during cardiac I/R injury.
Changyun Liu, Junxia Zhang, Yusi Chen, Geng Shen, Yufei Han, Zihao Zhou, Jinxuan Chen, Xuya Kang, Huilin Qu, Jiaxin Duanmu, Haibao Shang, Yingjia Li, Wei Huang, Yan Zhang   +13 more
wiley   +1 more source

Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5 Years

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Disopyramide is used to treat heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM) with known medium‐term efficacy and safety, while long‐term outcomes are unknown. Methods and Results A total of 92 consecutive
Daniele Massera, Mark V. Sherrid, Elizabeth Adlestein, Nadia Bokhari, Isabel C. Alvarez, Woon Y. Wu, Maria C. Reuter, Martin S. Maron, Barry J. Maron, Ethan J. Rowin   +9 more
doaj   +1 more source

Promoting Autophagy Mitigates Stress‐Induced Remodeling in Patient iPSC‐CMs with the Phospholamban R9C Mutation

Advanced Science, EarlyView.
The Phospholamban (PLN) R9C mutation reduces SERCA2a binding, increasing calcium recycling and baseline contractility. However, the excess of free PLN promotes pentamer formation, limiting phosphorylation and blunting β‐adrenergic signaling. Under cardiac stress, enhanced functional demands overwhelm proteostasis in PLN R9C cells, leading to misfolded ...
Qi Yu, Yawei Shen, Robert J. Barndt, Karim Sallam, Ying Tang, Cameron E. Brown, Xiao Li, Stephen Y. Chan, Joseph C. Wu, Qing Liu, Haodi Wu   +10 more
wiley   +1 more source

Echocardiographic Changes Following Surgical Myectomy in Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the SPIRIT‐HCM Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background In obstructive hypertrophic cardiomyopathy, myectomy improves symptoms, quality of life, and left ventricular (LV) outflow tract gradients. We prospectively evaluated the temporal changes in various echo parameters after myectomy.
Milind Y. Desai, Natalie Szpakowski, Albree Tower‐Rader, Barb Bittel, Agostina Fava, Susan Ospina, Bo Xu, Maran Thamilarasan, Amgad Mentias, Nicholas G. Smedira, Zoran B. Popovic   +10 more
doaj   +1 more source

Differences in microRNA-29 and Pro-fibrotic Gene Expression in Mouse and Human Hypertrophic Cardiomyopathy

Frontiers in Cardiovascular Medicine, 2019
Background: Hypertrophic cardiomyopathy (HCM) is characterized by myocyte hypertrophy and fibrosis. Studies in two mouse models (R92W-TnT/R403Q-MyHC) at early HCM stage revealed upregulation of endothelin (ET1) signaling in both mutants, but TGFβ ...
Yamin Liu, Yamin Liu, Junaid Afzal, Junaid Afzal, Styliani Vakrou, Gabriela V. Greenland, Gabriela V. Greenland, C. Conover Talbot, Virginia B. Hebl, Yufan Guan, Rehan Karmali, Jil C. Tardiff, Leslie A. Leinwand, Jeffrey E. Olgin, Samarjit Das, Ryuya Fukunaga, M. Roselle Abraham, M. Roselle Abraham   +17 more
doaj   +1 more source

Cardiac evaluation of young athletes: Time for a risk-based approach? [PDF]

, 2020
Pre-participation cardiovascular screening (PPCS) is recommended by several scientific and sporting organizations on the premise that early detection of cardiac disease provides a platform for individualized risk assessment and management; which has been
Drezner, JA, MacLachlan, H
core   +1 more source